BitMine buys 15,000 ETH from Ethereum Foundation OTC

Published: 2026-04-27 18:53:16 |

BitMine has bought 15,000 ETH from the Ethereum Foundation in two OTC transactions for $34.08 million, with March’s 5,000 ETH priced at $2,042.96/ETH and April’s 10,000 ETH at $2,387/ETH. This takes BitMine’s total ETH holdings to 5,078,386 ETH, above 4.2% of Ethereum’s circulating supply and closer to its 5% goal. The latest 15,000 ETH purchase is under 0.3% of BitMine’s broader portfolio, implying additional accumulation through other channels. The Ethereum Foundation’s sales are framed as ongoing treasury management under its 2025 policy, not a change in outlook. It has increasingly used staking/yield strategies and prefers private OTC transfers over public exchange sales. Separately, BitMine reports staking more than 3.7 million ETH, keeping a large share of its position working on-chain rather than sitting idle. For traders, the key takeaway is continued institutional spot demand for ETH via large-holder-to-corporate flows, with staking support that can reduce sell pressure. Spot accumulation signals can lend near-term sentiment support, though execution on higher prices (April vs March) may also temper immediate upside momentum.

Bullish

BitMine buying 15,000 ETH from the Ethereum Foundation via OTC is a direct spot-style accumulation signal for ETH. The purchase raises BitMine holdings above 4.2% of circulating supply and supports its plan toward a 5% target, reinforcing the narrative of continued institutional demand. In addition, BitMine reports staking more than 3.7 million ETH, which can reduce liquid sell pressure because a large portion of holdings is already earning on-chain yield. In the short term, traders may interpret the flow as supportive for ETH spot sentiment, especially since the Foundation’s actions are described as routine treasury management under its 2025 policy (not a bearish outlook shift). Over the longer term, if such selective transfers continue while the buyer remains heavily staked, ETH could benefit from steadier demand with less immediate supply overhang. The main caveat is that the April tranche was priced higher than March, which may limit near-term upside if markets have already partially repriced the news.